2. Academic Validation
  3. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab

The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab

  • Nat Commun. 2020 Jan 8;11(1):165. doi: 10.1038/s41467-019-13815-w.
Pascal Gasser 1 2 3,  Svetlana S Tarchevskaya 4,  Pascal Guntern 1 2 3,  Daniel Brigger 1 2,  Rahel Ruppli 1 2,  Noemi Zbären 1 2,  Silke Kleinboelting 4,  Christoph Heusser 5,  Theodore S Jardetzky 6,  Alexander Eggel 7 8
Affiliations

Affiliations

  • 1 Department of BioMedical Research, University of Bern, Bern, Switzerland.
  • 2 Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland.
  • 3 Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • 4 Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • 5 Pharmaceutical Research, Novartis AG, 4002, Basel, Switzerland.
  • 6 Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, 94305, USA. tjardetzky@stanford.edu.
  • 7 Department of BioMedical Research, University of Bern, Bern, Switzerland. alexander.eggel@dbmr.unibe.ch.
  • 8 Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland. alexander.eggel@dbmr.unibe.ch.
PMID: 31913280 DOI: 10.1038/s41467-019-13815-w
Abstract

Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.

Figures
Products